contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


pharma-equity-group-as-agreement-with-danske-bank-as-liquidity-provider-will-terminate-on-1-january-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Pharma Equity Group

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026 3 December 2025 Company Announcement no. 14 Pharma Equity Group A/S (“PEG”) announces...

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026 3 December 2025 Company Announcement no. 14 Pharma Equity Group A/S (“PEG”) announces that the Company’s agreement with Danske Bank as liquidity provider will terminate with effect from 1 January 2026. In connection with the termination of the agreement, the Company has evaluated its current market strategy. It is the management's assessment that, at this stage, greater value is created for shareholders by allocating resources to direct and targeted communication and Investor Relations activities rather than a contracted market maker arrangement. Consequently, PEG has chosen not to enter into an agreement with a new liquidity provider upon the expiration of the current agreement. The last trading day with Danske Bank acting as liquidity provider is 31 December 2025. The Company notes that this change may technically affect the liquidity of PEG’s share, including the bid-ask spread, as there will no longer be an external party obligated to provide bid and ask quotes from the turn of the year. This decision does not alter PEG’s overall strategic direction regarding business development. Further information: Christian Vinding Thomsen, Chairman of the Board, Tel. +45 2622 7222 Christian Tange, CEO, Tel. +45 29 48 84 17 About Pharma Equity Group A/S Pharma Equity Group (PEG) is a dynamic investment and development company within Life Science and is listed on Nasdaq Copenhagen. PEG identifies, acquires and develops innovation projects within pharmaceuticals, MedTech and other medical devices with a particular focus on early-stage innovation projects, especially those originating from Scandinavian research institutions. Through strategic capital allocation, strong governance with a dedicated investment committee, and an extensive industry network, PEG works to convert groundbreaking ideas into impactful healthcare solutions and products. The Company aims to build a balanced portfolio that creates continuous value and supports long-term growth—for the benefit of patients, healthcare systems and investors. Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/d1874647-20fb-421b-a72d-a8d349edb139">PEG company announcement 14 ENG</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0MjU2NCM0MDIyNzYyNDUjMjA5MTUzMQ==" alt=""> <img src="https://ml-eu.globenewswire.com/media/ZTZhNzJkYjMtNzA5MS00ZDFiLWIwYzAtZmU3Yzc5MzIxYjMxLTExMDMxMDItMjAyNS0xMi0wMy1lbg==/tiny/Pharma-Equity-Group-A-S.png" alt="">

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026